Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9245675 | 1.00 | GAA (0.58) | GAAAOC3ALDH1A1MAPTHTR1A | |
| SCHEMBL9085141 | 0.90 | AOC3 (0.56) | GAAAOC3ALDH1A1MAPTHTR1A | |
| SCHEMBL5488204 | 0.84 | AOC3 (0.58) | GAAAOC3ALDH1A1MAPTHTR1A | |
| SCHEMBL6482817 | 0.83 | AOC3 (0.61) | GAAAOC3ALDH1A1MAPTCA12 | |
| SCHEMBL4372787 | 0.83 | AOC3 (0.61) | GAAAOC3ALDH1A1MAPTCA12 | |
| SCHEMBL17660055 | 0.83 | AOC3 (0.61) | GAAAOC3ALDH1A1MAPTCA12 | |
| SCHEMBL25189393 | 0.82 | AOC3 (0.59) | GAAAOC3ALDH1A1MAPTHTR1A | |
| SCHEMBL6055130 | 0.82 | AOC3 (0.56) | GAAAOC3ALDH1A1MAPTHTR1A | |
| SCHEMBL3918376 | 0.82 | GAA (0.56) | GAAAOC3ALDH1A1MAPTHTR1A | |
| SCHEMBL9298171 | 0.82 | AOC3 (0.61) | GAAAOC3ALDH1A1MAPTHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5395983-A | Process for producing 1-phenyl-1,3-propanediols having high optical purtiy | CHISSO CORPORATION (JP) | 1995-03-07 | — | — | US | claimed |
| CN-117820101-A | Amplified preparation method of Edwan sweet | 上海再启生物技术有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-111875666-B | Method for synthesizing Edwarden sweet | 辽宁启康生物科技有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-111875666-A | Method for synthesizing Edwarden sweet | 辽宁启康生物科技有限公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-104169241-B | Method for preparing chiral ketone from aldehyde | 南洋理工大学 | 2016-10-05 | — | — | CN | disclosed |
| EP-2061778-A1 | METHOD FOR PRODUCING CYCLIC UNSATURATED COMPOUND | Nippon Shokubai Co., Ltd. (JP) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008023823-A1 | METHOD FOR PRODUCING CYCLIC UNSATURATED COMPOUND | NIPPON SHOKUBAI CO., LTD. (JP) | 2008-02-28 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| WO-2005003140-A1 | 4-OXO-4,7-DIHYDROTHIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | AGOURON PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-5395983-A | Process for producing 1-phenyl-1,3-propanediols having high optical purtiy | CHISSO CORPORATION (JP) | 1995-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | GAA 2059/4885AOC3 872/4885ALDH1A1 3567/4885 |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, IRF3, BRD4 | GAA 3007/4885AOC3 1464/4885ALDH1A1 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.